Levodopa therapy reduces DNA damage in peripheral blood cells of patients with Parkinson's disease.
Oxidative stress seems to play a major role in the pathogenesis of neurodegeneration. In Parkinson's disease (PD) patients, the dopaminergic neurons are subjected to oxidative stress resulting from reduced levels of antioxidant defenses such as glutathione and high amount of intracellular iron. Levodopa (LD) is widely used for the symptomatic treatment of PD, but its role in oxidative damage control is still unclear. The aim of this study was to analyze the presence of DNA damage in peripheral blood lymphocytes (PBL) of PD patients, during a washout and a controlled LD dosage and to evaluate the oxidative damage fluctuation after LD intake. The standard and the Fpg-modified version of Comet assay were applied in analyzing DNA damage in PBL from blood samples of nine PD patients and nine matched controls. Due to the limited number of patients we cannot reach definite conclusions even if our data confirm the accumulation of DNA lesions in PD patients; these lesions decrease after LD intake.
Cornetta
T
T
Department of Biology, "Roma Tre" University, Rome, Italy.
Palma
S
S
Aprile
I
I
Padua
L
L
Tonali
P
P
Testa
A
A
Cozzi
R
R
D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001773:Blood Cells / Q000187:drug effects* / Q000378:metabolism; D020552:Comet Assay; D004249:DNA Damage / Q000187:drug effects*; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D007980:Levodopa / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D010300:Parkinson Disease / Q000188:drug therapy*
D000978:Antiparkinson Agents; D007980:Levodopa